BridgeBio publishes genetic, health data in American Journal of Human Genetics

BridgeBio (BBIO) Pharma published an analysis of genetic and health data from more than 700,000 individuals in the American Journal of Human Genetics, confirming prior estimates of the genetic prevalence of autosomal dominant hypocalcemia type 1 and underscoring opportunities to elevate diagnostic suspicion. CALIBRATE, BridgeBio’s Phase 3 clinical trial of encaleret for ADH1, a condition caused by activating variants of the CASR, is fully enrolled with 71 participants. The registrational study is the largest prospective interventional study ever to be conducted in ADH1. The Company expects to report topline results in the second half of 2025. If successful, encaleret would be the first approved therapy for individuals living with ADH1. The Company also intends to initiate a registrational study of encaleret in chronic hypoparathyroidism, another condition linked with the newly found CASR allelic series, in 2026.